$BFLY

Butterfly Network, Inc. (BFLY): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Butterfly Network, Inc. (BFLY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. bfly-20260805 0001804176 False 0001804176 2026-08-05 2026-08-05 0001804176 us-gaap:CommonStockMember 2026-08-05 2026-08-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Ac

Original reporting
Published Aug 11, 2026, 12:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$BFLY
Neutral
medium confidence
Mentioned
$BFLY
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BFLYNeutralLow
01

Why it matters

Dr. Erica Schwartz resigned as a director effective upon her Aug. 5, 2026 Senate confirmation as Director of the Centers for Disease Control and Prevention. The filing explicitly states the resignation was not due to disagreements with the company on operations, policies, or practices.

02

Market read

This is a governance update with limited fundamental information content, but it can still influence investor sentiment around board oversight.

03

What to watch

Traders may want to check whether the company simultaneously appointed a replacement director or reassigned committee roles, which can matter for governance-sensitive investors.

Relevance 6/10Novelty 3/10Timing: filed Aug. 11, 2026, covering a director resignation effective Aug. 5, 2026

Background

The company filed an SEC Form 8-K under Item 5.02 regarding director departure and related officer/director appointment and compensatory arrangements.

Company-level read

Ticker impact

$BFLYNeutralMedium confidence
Context

Butterfly Network filed an 8-K saying director Dr. Erica Schwartz resigned after Senate confirmation as CDC director, effective Aug. 5, 2026.

Expected impact

Limited immediate price impact expected; any reaction would likely be sentiment/governance-related rather than fundamentals.

Evidence & confidence

The filing describes a resignation tied to a public-sector appointment and states it was not due to disagreements on company operations, policies, or practices.

Market effects

Minimal sector read-through; this is a governance event rather than a product, regulatory, or financial datapoint.

No clear regional market linkage beyond general small-cap sentiment.

Low; the event is primarily company-specific board governance.

Counterpoint

Even without operational disagreement, losing a high-profile director could raise perceived execution or oversight risk, especially if she chaired key committees.

Key entities

  • Butterfly Network, Inc.

    US-listed medical technology company filing the 8-K (BFLY).

  • Dr. Erica Schwartz

    Resigning director whose resignation became effective after Senate confirmation as CDC Director.

  • Centers for Disease Control and Prevention (CDC)

    Federal agency where Dr. Schwartz was confirmed as Director.

Related articles

$BFLYMed

Butterfly Network (BFLY) Is Up 24.2% After Raising 2026 Guidance And Narrowing Losses - Has The Bull Case Changed?

Butterfly Network (BFLY) shares rose 24.2% after the company reported Q2 2026 revenue of $32.61M and a reduced net loss of $12.91M, and raised 2026 revenue guidance to $119M to $123M. The article cites improving losses and momentum in Embedded partnerships and enterprise point-of-care ultrasound, while noting ongoing cash burn and potential dilution risks.

$BFLYMedAI 9/10

Butterfly (BFLY) Q2 2026 Earnings Call Transcript

Butterfly Network (BFLY) reported Q2 2026 revenue of $32.6M, up 39% y/y, driven by Embedded revenue of $10.8M (+439%). Gross profit rose to $23.3M and gross margin to 71%. Adjusted EBITDA loss narrowed to $1.4M. Q3 revenue guidance is $26M to $30M, and FY2026 revenue guidance is $119M to $123M.

$BFLYMedAI 8/10

Butterfly Network, Inc. Q2 2026 Earnings Call Summary

Butterfly Network, Inc. reported Q2 2026 progress driven by POCUS, Home and Community Care, and Embedded partnerships. Embedded revenue rose 439% on the Midjourney partnership. Gross margin was 71%. Full-year 2026 revenue guidance was raised to $119 million-$123 million. Home and Community Care first commercial implementation starts Oct 1, with revenue in Q4 2026.

$BFLYMedAI 8/10

Butterfly (BFLY) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Financial Officer - John Doherty Chairman and Chief Executive Officer - Joseph DeVivo TAKEAWAYS Revenue -- $32.6 million, an increase of 39% year over year driven primarily by the growth of the Butterfly Embedded segment. Embedded Revenue -- $10.8 million, representing 439% year-over-year growth due to development work and milestones from the Midjourney partnership.

$BFLYHighAI 9/10

Butterfly Network, Inc. (BFLY): Results of Operations and Financial Condition

Butterfly Network, Inc. (BFLY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bfly-20260730xexx991.htm EX-99.1 Document Exhibit 99.1 Butterfly Network Reports Second Quarter 2026 Financial Results Delivered Record Revenue and Adjusted EBITDA Loss Above Guidance • Raised full year Revenue and Improved Adjusted EBITDA Guidance • Delivered quarterly